MicroRNA-21 Promotes Glioblastoma Tumorigenesis by Down-regulating Insulin-like Growth Factor-binding Protein-3 (IGFBP3)*

Background: miR-21 is overexpressed in many human cancers, including glioblastoma. Results: Insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) is a novel miR-21 target gene and inhibits gliomagenesis in vitro and in vivo. Conclusion: miR-21 down-regulates IGFBP3, which acts as a tumor suppressor in human glioblastoma. Significance: IGFBP3 may have promise as a therapeutic target and prognostic marker for glioblastoma. Despite advances in surgery, imaging, chemotherapy, and radiation, patients with glioblastoma multiforme (GBM), the most common histological subtype of glioma, have an especially dismal prognosis; >70% of GBM patients die within 2 years of diagnosis. In many human cancers, the microRNA miR-21 is overexpressed, and accumulating evidence indicates that it functions as an oncogene. Here, we report that miR-21 is overexpressed in human GBM cell lines and tumor tissue. Moreover, miR-21 expression in GBM patient samples is inversely correlated with patient survival. Knockdown of miR-21 in GBM cells inhibited cell proliferation in vitro and markedly inhibited tumor formation in vivo. A number of known miR-21 targets have been identified previously. By microarray analysis, we identified and validated insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a novel miR-21 target gene. Overexpression of IGFBP3 in glioma cells inhibited cell proliferation in vitro and inhibited tumor formation of glioma xenografts in vivo. The critical role that IGFBP3 plays in miR-21-mediated actions was demonstrated by a rescue experiment, in which IGFBP3 knockdown in miR-21KD glioblastoma cells restored tumorigenesis. Examination of tumors from GBM patients showed that there was an inverse relationship between IGFBP3 and miR-21 expression and that increased IGFBP3 expression correlated with better patient survival. Our results identify IGFBP3 as a novel miR-21 target gene in glioblastoma and suggest that the oncogenic miRNA miR-21 down-regulates the expression of IGFBP3, which acts as a tumor suppressor in human glioblastoma.

[1]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[2]  L. Pfeffer,et al.  The Curcumin Analog EF24 Targets NF-κB and miRNA-21, and Has Potent Anticancer Activity In Vitro and In Vivo , 2013, PloS one.

[3]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[4]  Junming Yue,et al.  MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells* , 2011, The Journal of Biological Chemistry.

[5]  Yong Li,et al.  Apoptosis and the target genes of microRNA-21 , 2011, Chinese journal of cancer.

[6]  L. Pfeffer,et al.  Cancer esearch apeutics , Targets , and Chemical Biology Induces miR-21 through a Signal Transducer and ivator of Transcription 3 – Dependent Pathway as a R pressive Negative Feedback on IFN-Induced Apoptosis , 2010 .

[7]  Andreas von Deimling,et al.  Identification of diagnostic serum protein profiles of glioblastoma patients , 2010, Journal of Neuro-Oncology.

[8]  K. Thennarasu,et al.  Grade-Specific Expression of Insulin-like Growth Factor–Binding Proteins-2, -3, and -5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[9]  Silvia Veneroni,et al.  miR-21: an oncomir on strike in prostate cancer , 2010, Molecular Cancer.

[10]  Zheng Yang,et al.  BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR , 2009, Molecular Cancer Therapeutics.

[11]  Zhenghe Wang,et al.  microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. , 2009, Cancer research.

[12]  E. Holland,et al.  Modeling Adult Gliomas Using RCAS/t-va Technology. , 2009, Translational oncology.

[13]  P. Yamada,et al.  Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. , 2009, American journal of physiology. Cell physiology.

[14]  Carsten Denkert,et al.  Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. , 2009, Cancer research.

[15]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[16]  J. Meyerhardt,et al.  Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 , 2008, Clinical Cancer Research.

[17]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[18]  P. Torng,et al.  Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma , 2008, Oncogene.

[19]  Shuomin Zhu,et al.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.

[20]  Jörg Hackermüller,et al.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.

[21]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[22]  J. Trojan.,et al.  Insulin-like growth factor type I biology and targeting in malignant gliomas , 2007, Neuroscience.

[23]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[24]  G. Fuller,et al.  Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study , 2006, Technology in cancer research & treatment.

[25]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[27]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[28]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[29]  Hiroshi Watanabe,et al.  Redundancy of Radioresistant Signaling Pathways Originating from Insulin-like Growth Factor I Receptor* , 2002, The Journal of Biological Chemistry.

[30]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[31]  L. Graham,et al.  Role of insulin‐like growth factor binding protein‐3 in breast cancer cell growth , 2002, Microscopy research and technique.

[32]  Eva L Feldman,et al.  Control of cell survival by IGF signaling pathways. , 2002, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[33]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[34]  M. Kattan,et al.  Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Martine J Jager,et al.  Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. , 2002, Investigative ophthalmology & visual science.

[36]  S. Andò,et al.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. , 2001, Cancer research.

[37]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[38]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[41]  L. Pfeffer,et al.  STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. , 1997, Science.

[42]  M. Tykocinski,et al.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. , 1992, Proceedings of the National Academy of Sciences of the United States of America.